Anne D. Lewis

Dr. Anne D. Lewis

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMariya B. Shapiro
Mariya B. Shapiro
TCTracy Cheever
Tracy Cheever
DMDelphine C. Malherbe
Delphine C. Malherbe
SPShilpi Pandey
Shilpi Pandey
JRJason Reed
Jason Reed
NHNancy L. Haigwood
Nancy L. Haigwood
Vertical transmission accounts for most human immunodeficiency virus (HIV) infection in children, and treatments for newborns are needed to abrogate infection or limit disease progression. We showed previously that short-term broadly neutralizing antibody (bNAb) therapy given 24 h after oral exposure cleared simian-human immunodeficiency virus (SHIV) in a macaque model of perinatal infection. Here, we report that all infants given either a single dose of bNAbs at 30 h, or a 21-day triple-drug ART regimen at 48 h, are aviremic with almost no virus in tissues. In contrast, bNAb treatment beginning at 48 h leads to tight control without adaptive immune responses in half of animals. We conclude that both bNAbs and ART mediate effective post-exposure prophylaxis in infant macaques within 30–48 h of oral SHIV exposure. Our findings suggest that optimizing the treatment regimen may extend the window of opportunity for preventing perinatal HIV infection when treatment is delayed.

14 August 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DRDavide F. Robbiani
Davide F. Robbiani
POPriscilla C. Olsen
Priscilla C. Olsen
FCFederico Costa
Federico Costa
Qiao WangQiao Wang
Qiao Wang
TOThiago Y. Oliveira
Thiago Y. Oliveira
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Zika virus (ZIKV) infection during pregnancy causes congenital abnormalities, including microcephaly. However, rates vary widely, and the contributing risk factors remain unclear. We examined the serum antibody response to ZIKV and other flaviviruses in Brazilian women giving birth during the 2015–2016 outbreak. Infected pregnancies with intermediate or higher ZIKV antibody enhancement titers were at increased risk to give birth to microcephalic infants compared with those with lower titers (P < 0.0001). Similarly, analysis of ZIKV-infected pregnant macaques revealed that fetal brain damage was more frequent in mothers with higher enhancement titers. Thus, features of the maternal antibodies are associated with and may contribute to the genesis of ZIKV-associated microcephaly.

1 December 2019 in Experimental Eye Research
Verified
Journal Article
Closed access
SPSamuel M. Peterson
Samuel M. Peterson
TMTrevor J. McGill
Trevor J. McGill
TPTeresa Puthussery
Teresa Puthussery
JSJonathan Stoddard
Jonathan Stoddard
LRLauren Renner
Lauren Renner
MNMartha Neuringer
Martha Neuringer

1 April 2022 in Toxicologic Pathology
Verified
Journal Article
Closed access
AJAmanda L. Johnson
Amanda L. Johnson
RKRebekah I. Keesler
Rebekah I. Keesler
ALAnne D. Lewis
Anne D. Lewis
JRJ. Rachel Reader
J. Rachel Reader
SLSteven T. Laing
Steven T. Laing
Rhesus and cynomolgus macaques are the most frequently used nonhuman primate (NHP) species for biomedical research and toxicology studies of novel therapeutics. In recent years, there has been a shortage of laboratory macaques due to a variety of competing factors. This was most recently exacerbated by the surge in NHP research required to address the severe acute respiratory syndrome (SARS)-coronavirus 2 pandemic. Continued support of these important studies has required the use of more varied cohorts of macaques, including animals with different origins, increased exposure to naturally occurring pathogens, and a wider age range. Diarrhea and diseases of the gastrointestinal tract are the most frequently occurring spontaneous findings in macaques of all origins and ages. The purpose of this review is to alert pathologists and scientists involved in NHP research to these findings and their impact on animal health and study endpoints, which may otherwise confound the interpretation of data generated using macaques.

1 December 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AOAfam A Okoye
Afam A Okoye
MDMaren Q. DeGottardi
Maren Q. DeGottardi
YFYoshinori Fukazawa
Yoshinori Fukazawa
MVMukta Vaidya
Mukta Vaidya
CAChike O Abana
Chike O Abana
LPLouis J. Picker
Louis J. Picker
Although IL-15 has been implicated in the pathogenic hyperimmune activation that drives progressive HIV and SIV infection, as well as in the generation of HIV/SIV target cells, it also supports NK and T cell homeostasis and effector activity, potentially benefiting the host. To understand the role of IL-15 in SIV infection and pathogenesis, we treated two cohorts of SIVmac239-infected rhesus macaques (RM; Macaca mulatta), one with chronic infection, the other with primary infection, with a rhesusized, IL-15–neutralizing mAb (versus an IgG isotype control) for up to 10 wk (n = 7–9 RM per group). In both cohorts, anti–IL-15 was highly efficient at blocking IL-15 signaling in vivo, causing 1) profound depletion of NK cells in blood and tissues throughout the treatment period; 2) substantial, albeit transient, depletion of CD8+ effector memory T cells (TEM) (but not the naive and central memory subsets); and 3) CD4+ and CD8+ TEM hyperproliferation. In primary infection, reduced frequencies of SIV-specific effector T cells in an extralymphoid tissue site were also observed. Despite these effects, the kinetics and extent of SIV replication, CD4+ T cell depletion, and the onset of AIDS were comparable between anti–IL-15– and control-treated groups in both cohorts. However, RM treated with anti–IL-15 during primary infection manifested accelerated reactivation of RM rhadinovirus. Thus, IL-15 support of NK cell and TEM homeostasis does not play a demonstrable, nonredundant role in SIV replication or CD4+ T cell deletion dynamics but may contribute to immune control of oncogenic γ-herpesviruses.

26 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
BQBenjamin K. Quintel
Benjamin K. Quintel
KPKamm Prongay
Kamm Prongay
ALAnne D. Lewis
Anne D. Lewis
HRHans-Peter Raué
Hans-Peter Raué
SHSara Hendrickson
Sara Hendrickson
IAIan J. Amanna
Ian J. Amanna
We describe a novel vaccine that provides protection against Campylobacter -associated diarrhea in a natural exposure model.